Literature DB >> 14962966

Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis.

M Fathi1, M Dastmalchi, E Rasmussen, I E Lundberg, G Tornling.   

Abstract

OBJECTIVES: To estimate the prevalence and predictors of interstitial lung disease in newly diagnosed polymyositis and dermatomyositis.
METHODS: A prospective study in which consecutive patients with newly diagnosed poly- and dermatomyositis, regardless of clinical symptoms of pulmonary disease, were investigated with chest x ray, high resolution computed tomography (HRCT), pulmonary function tests, and biochemical and autoantibody analysis. Patients with inclusion body myositis, malignancy, other defined inflammatory connective tissue diseases (CTDs), or antibody profile indicating other CTDs were excluded.
RESULTS: Between March 1998 and September 2000, 26 new cases of poly- or dermatomyositis were diagnosed; 17 of those patients were included in the study. Interstitial lung disease (ILD), defined as radiological signs on chest x ray examination/HRCT or restrictive ventilatory defect, were found in 11 (65%) patients and were more common in men than in women. Arthritis and occurrence of anti-Jo-1 antibodies were found more often in patients with ILD than in those without. There was no statistically significant association between respiratory symptoms, other serological or laboratory variables and ILD.
CONCLUSIONS: ILD is a common early manifestation in patients with poly- and dermatomyositis and is not always related to clinical symptoms. Chest x ray examination, HRCT, pulmonary function tests, and analysis of anti-Jo-1 antibodies should be included in the initial investigation of patients with myositis regardless of respiratory symptoms.

Entities:  

Mesh:

Year:  2004        PMID: 14962966      PMCID: PMC1754925          DOI: 10.1136/ard.2003.006122

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  27 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide.

Authors:  W S BLAKEMORE; R E FORSTER; J W MORTON; C M OGILVIE
Journal:  J Clin Invest       Date:  1957-01       Impact factor: 14.808

3.  Antibodies to Jo-1 and Ro-52: why do they go together?

Authors:  P J Venables
Journal:  Clin Exp Immunol       Date:  1997-09       Impact factor: 4.330

4.  Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings.

Authors:  H D Tazelaar; R W Viggiano; J Pickersgill; T V Colby
Journal:  Am Rev Respir Dis       Date:  1990-03

Review 5.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

Review 6.  Pulmonary disease in polymyositis/dermatomyositis.

Authors:  B F Dickey; A R Myers
Journal:  Semin Arthritis Rheum       Date:  1984-08       Impact factor: 5.532

7.  The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies.

Authors:  M B Frank; V McCubbin; E Trieu; Y Wu; D A Isenberg; I N Targoff
Journal:  J Autoimmun       Date:  1999-03       Impact factor: 7.094

8.  Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases.

Authors:  J Benbassat; D Gefel; K Larholt; S Sukenik; V Morgenstern; A Zlotnick
Journal:  Arthritis Rheum       Date:  1985-03

Review 9.  Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders.

Authors:  P H Plotz; M Dalakas; R L Leff; L A Love; F W Miller; M E Cronin
Journal:  Ann Intern Med       Date:  1989-07-15       Impact factor: 25.391

10.  Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients.

Authors:  E T Koh; A Seow; B Ong; P Ratnagopal; H Tjia; H H Chng
Journal:  Ann Rheum Dis       Date:  1993-12       Impact factor: 19.103

View more
  55 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

2.  Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.

Authors:  Pamela A Morganroth; Mary Elizabeth Kreider; Joyce Okawa; Lynne Taylor; Victoria P Werth
Journal:  Arch Dermatol       Date:  2010-07

Review 3.  [Pulmonary manifestations in rheumatic systemic diseases].

Authors:  T Schlossbauer; C Becker-Gaab; R Eibel
Journal:  Radiologe       Date:  2005-07       Impact factor: 0.635

4.  Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.

Authors:  Julio A Huapaya; Leann Silhan; Iago Pinal-Fernandez; Maria Casal-Dominguez; Cheilonda Johnson; Jemima Albayda; Julie J Paik; Abanti Sanyal; Andrew L Mammen; Lisa Christopher-Stine; Sonye K Danoff
Journal:  Chest       Date:  2019-06-22       Impact factor: 9.410

5.  Successful use of extracorporeal membrane oxygenation for severe interstitial lung disease in a child with dermatomyositis.

Authors:  Francesco Zulian; Maria Martha Martinez Toledo; Angela Amigoni; Giorgia Martini; Caterina Agosto; Andrea Pettenazzo
Journal:  Intensive Care Med       Date:  2007-06-27       Impact factor: 17.440

6.  [Early symptoms of dermatomyositis and antisynthetase syndrome].

Authors:  B Maurer
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

Review 7.  Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review.

Authors:  Dan Chen; Xiao-bing Wang; Yan Zhou; Xiao-chun Zhu
Journal:  Rheumatol Int       Date:  2013-05-29       Impact factor: 2.631

Review 8.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

9.  Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease.

Authors:  Thomas J Richards; Aaron Eggebeen; Kevin Gibson; Samuel Yousem; Carl Fuhrman; Bernadette R Gochuico; Noreen Fertig; Chester V Oddis; Naftali Kaminski; Ivan O Rosas; Dana P Ascherman
Journal:  Arthritis Rheum       Date:  2009-07

Review 10.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.